Mitglied bei

 

  • Startseite

  • ME/CFS - was ist das?

  • Artikel des Monats

  • Kommentare des Monats 

  • Medienberichte

  • News

  • Broschüren zu Diagnose und Behandlung 

  • Häufig gestellte Fragen zu ME/CFS

  • Humor und Kreatives

  • Weiterführende Links

  • Impressum/Disclaimer

  • Spendenkonto

  •       

    Suche auf cfs-aktuell:

     

    Eine weitere Suchmöglichkeit besteht darin, z.B. bei www.google.de das Suchwort einzugeben und dann nach einem Leerzeichen den Zusatz site:www.cfs-aktuell.de

    Sie erhalten dann alle Seiten auf cfs-aktuell.de, auf denen der gesuchte Begriff vorkommt.

    Artikel des Monats Februar 2011 Teil 3

    6. Internationale Invest in ME/CFS Konferenz

    am 20. Mai 2011 in London

     

     

    Dies ist die sechste Internationale Invest in ME Konferenz in Folge.

    Sie wird am Freitag, den 20. Mai 2011 in Westminster, London stattfinden und knüpft an die vorangegangenen Konferenzen in den Jahren zuvor an.

    Wie auch in früheren Jahren ist das Ziel, das Wissen um die neurologische Erkrankung ME/CFS zu verbreiten. Diese Konferenz wird sich auf die Notwendigkeit von biomedizinischer Forschung zur Entwicklung von Behandlungs- und Heilungsmöglichkeiten für diese verheerende Krankheit konzentrieren , eine Krankheit, die in Großbritannien fünf mal häufiger ist als HIV/AIDS und deren Erforschung dennoch mit vergleichsweise wenig finanziellen Mitteln unterstützt wurde.

     

    As in previous years Invest in ME aim to raise awareness of the neurological illness myalgic encephalomyelitis (ME/CFS). This conference will highlight the need for a national strategy for biomedical research which will lead to treatment and a cure for this devastating illness - an illness which is 5 times more common in the UK than HIV/AIDS - yet which has had comparatively little funding spent on biomedical research.
     

    Our 2008 conference in London focused on Sub Grouping and Treatments and showed indisputable proof from leading ME/CFS experts regarding the pathology of this illness.
    Our 2009 conference concentrated on the severely-affected people with ME.
    Our 2010 conference concentrated on the new era of ME/CFS research which had been created by awareness of the XMRV retrovirus.

    With the discovery of the xenotropic murine leukemia virus-related virus (XMRV) retrovirus in patients with ME/CFS by the Whittemore-Peterson Institute, the US National Cancer Institute and the Cleveland Clinic of Ohio, we publicised this major breakthrough in the understanding and treatment of ME/CFS and in the implications in ME/CFS in our 2010 conference.

    For 2011 the way forward must be to focus on translational biomedical research into ME/CFS and this means initiating clinical trials using homogeneous patient cohorts and correct clinical guidelines.

    Therefore our 2011 conference slogan is -

    The Way Forward for ME - A Case for Clinical Trials

    and the theme is

    The Need for Guidelines, Treatments and Clinical Trials  for ME/CFS

    The education of healthcare staff about ME/CFS now needs to break with the past and reflect the new found knowledge about the pathogenesis of ME/CFS which high quality biomedical research is providing.

    The conference will be oriented toward providing healthcare staff and others with knowledge of the latest research and the biomarkers which allow appropriate treatments to be prescribed.

    However, apart from a knowledge of the biomedical research which is ongoing it is necessary for healthcare staff to be aware of the multiple symptoms exhibited by ME patients and of the possible treatments available.

    Research data and experiences of  treating ME/CFS will be presented as will  findings from the latest biomedical research. The time is right for moving ahead with new findings and embarking on clinical trials to enable rapid progress to be made with discovery of effective treatments.

    The presenters at the conference represent the world's most current ME/CFS knowledgebase regarding ME/CFS.

    The conference provides information and opportunities which are not available via the internet. One of the most important aspects at previous IiME conferences has been the creation or resumption of the unique networking opportunities available with some of the most renowned experts on ME/CFS in the world.

    Return to top of page

    Who should attend?

    The conference will appeal to healthcare professionals, doctors, nurses, paediatricians, occupational therapists, researchers, ME/CFS support groups, people with ME/CFS and those working in social services, educational support and the media.

    The conference provides an opportunity for people within government, health departments, social services and education to be able to be informed of the true nature of ME/CFS and of the current status of diagnosis, treatment and current/future biomedical research possibilities.

     

     

    International ME/CFS Conference 2011

    Welcome to the 6th Invest in ME International ME/CFS Conference 2011 in Westminster, London, UK, on 20th May 2011.

     

    Today Invest in ME announce the speakers at the conference (see below).

    The key to resolving, treating and curing ME/CFS lies in biomedical research. Healthcare staff need to be aware of the latest biomedical research into ME/CFS as well as the multiple symptoms exhibited by ME/CFS patients and of the possible treatments available.

    The education of healthcare staff about ME/CFS now needs to break with the past and reflect the newfound knowledge about the pathogenesis of ME/CFS which high quality biomedical research is providing.

    The conference will be oriented toward providing healthcare staff and others with knowledge of the latest research, clinical trials and the biomarkers which allow appropriate treatments to be prescribed.

    The Invest in ME biomedical research conferences began in 2006 and was followed with a 2-day conference in 2007. Our 2008 conference focused on Sub Grouping and Treatments and showed indisputable proof from leading ME/CFS experts regarding the organic basis and pathology of this illness. Our 2009 conference was oriented toward the severely-affected patients with ME/CFS.

    Our 2010 conference heralded a new era of ME/CFS research based on biomedical research which had energised and empowered patients after the discovery of the xenotropic murine leukemia virus-related virus (XMRV) in patients with ME/CFS by the Whittemore-Peterson Institute, the US National Cancer Institute and the Cleveland Clinic of Ohio.

    Now the way forward for ME is to bring new awareness of this disease to researchers and potential funders of biomedical research and instigate clinical trials to give healthcare providers the tools to help their patients. 

    Translational biomedical research - an iterative feedback of information between the basic and clinical research domains in order to accelerate knowledge translation from the lab to the bedside and back to the lab again - needs to be implemented to translate the findings in basic research more quickly and efficiently into medical practice. This will produce more meaningful health outcomes and facilitate the sharing of repositories and research-based facilities and laboratories. This is the model IiME are attempting to promote in the proposal for a UK Centre of Excellence based in Norwich [click here].

    Research data and experiences of managing and treating ME/CFS will be presented as will findings from the latest biomedical research.

    The time is right for a scientific approach to research and treatment associated with ME/CFS.

    Conference Speakers

    Invest in ME are pleased to announce the following speakers at the conference-

    Dr. David Bell MD  
    Dr. David Bell graduated from Harvard College and gained an MD degree at Boston University. Post doctoral training in paediatrics was completed with subspecialty training in Paediatric Behavior and Developmental Disorders. In 1978 he began work at the University of Rochester and then began a private practice in the town of Lyndonville, New York. In 1985 nearly 220 persons became ill with an illness subsequently called chronic fatigue syndrome in the communities surrounding Lyndonville, New York. This illness cluster began a study of the illness which continues today. Dr. David Bell is the author or co-author of numerous scientific papers on CFS, and, in 2003 was named Chairman of the Advisory Committee for Chronic Fatigue Syndrome of the Department of Health and Human Services. Publications include A Disease of A Thousand Names, (1988) and The Doctor's Guide to Chronic Fatigue Syndrome, (1990). Dr. Bell is currently performing ME/CFS research into the XMRV retrovirus. 

    Mrs. Annette Whittemore
    Founder and President of the Whittemore Peterson Institute for Neuroimmune Diseases, Reno, Nevada, USA.  The Institute is located on the medical campus of the University of Nevada. Its mission is to serve those with complex neuro-immune diseases such as ME/CFS, viral induced central nervous system dysfunction and fibromyalgia. Annette Whittemore graduated in Elementary and Special Education at the University of Nevada and taught children with neuro-cognitive deficits, such as those found in autism, ADD, and learning disabilities. As the president and director of the current operations at the Institute Annette supports the basic and clinical research program, and actively recruits physicians and other support personnel for the Institute.

     

    Dr Judy Mikovits PhD  
    Judy Mikovits is Research Director at the Whittemore Peterson Institute for Neuro-Immune Diseases and has co-authored over 40 peer reviewed publications that address fundamental issues of viral pathogenesis, hematopoiesis and cytokine biology. Formally trained as a cell biologist, molecular biologist and virologist, Dr. Mikovits has studied the immune response to retroviruses and herpes viruses including HIV, SIV, HTLVI, HERV, HHV6 and HHV8 with a special emphasis on virus host cell interactions in cells of the hematopoietic system including hematopoietic stem cells (HSC).
    Dr Mikovits is one of the authors of the ground-breaking study published in Science magazine in October 2009 which detected XMRV in CFS patients  (Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome) and is a member of the US Department of Health and Human Services Blood Working Group.

    Professor Kenny De Meirleir MD, PhD
    Professor De Meirleir is a world renowned researcher of ME/CFS. He is full professor of physiology, pathophysiology and medicine at the Virje Universitet Brussel and practices Internal Medicine at Himmunitas Foundation also in Brussels and has published several hundred peer reviewed articles and is co-author of the book 'Chronic Fatigue Syndrome: a biological approach' and was co-editor of the Journal of Chronic Fatigue Syndrome, and reviewer for more than 10 other medical journals.  Professor De Meirleir was one of four international experts on the panel that developed the Canadian Consensus Document for ME/CFS. He assesses/treats thousands of ME/CFS patients annually and is the most experienced researcher in Europe regarding ME/CFS. His research activities in ME/CFS date back to 1990. His other research activities in exercise physiology, metabolism and endocrinology have led to the Solvay Prize and the NATO research award. 

    Dr Jose Montoya MD
    Associate Professor of Medicine (Infectious Diseases and Geographic Medicine), Stanford University, California, USA and Director, Toxoplasmosis National Reference Laboratory at Palo Alto Medical Foundation, California, USA. He completed his residency in Internal Medicine at Tulane University. Dr Montoya then completed his post-doctoral fellowship at Stanford University. Currently, he is serving as an associate professor in Infectious Diseases at Stanford. He has worked on a wide variety of projects in this field including research focused on the efficacy of new smallpox vaccines. Additionally, he is the founder and co-director of the Immunocompromised Host Service and works at the Positive Care Clinic at Stanford. Dr. Montoya specializes in toxoplasmosis and infectious diseases particularly as it pertains to cardiac transplants and AIDS patients. Dr. Montoya is also the recipient of many Stanford teaching awards, including the Bloomfield, Ebaugh, Kaiser and Rytand awards.

    Currently Stanford University is taking a very active role in the study of patients with unexplained chronic illnesses such as chronic Lyme disease, chronic fatigue syndrome and multiple sclerosis.  

    Dr. John Chia MD
    Dr Chia is an infectious disease specialist, Torrance, California, USA. He has published research ("Chronic fatigue syndrome associated with chronic enterovirus infection of the stomach") on the role of enteroviruses in the aetiology of ME/CFS - an area which has been implicated as one of the causes by a number of studies. There are more than 70 different types of enteroviruses that can affect the central nervous system, heart and muscles, all of which is consistent with the symptoms of ME/CFS.  By analyzing samples of stomach tissue from 165 patients with CFS, Dr. Chia's team discovered that 82% of these individuals had high levels of enteroviruses in their digestive systems. Dr Chia's research may result in the development of antiviral drugs to treat the debilitating symptoms of ME/CFS. 

    Professor Olav Mella MD, PhD and/or Dr Øystein Fluge MD, PhD (tbc)
    from the Institute of Medicine, Section of Oncology, University of Bergen, Norway and Department of Oncology and Medical Physics, Haukeland University Hospital,  Bergen, Norway.
    Professor Mella and Dr Fluge have performed clinical trials to test the benefit of B-cell depletion therapy using Rituximab in ME/CFS patients. 

     

     
    We hope to have news of additional speakers shortly.

    Also present at the conference will be representatives of the European ME Alliance (EMEA) as the EMEA AGM takes place after the conference. 

    CPD Accreditation from the Royal colleges has been applied for and we hope to obtain the maximum credits for the conference, as in previous years.


     


     

    Discounted rate - Sponsor a Medic IiME are again offering a discounted rate for healthcare staff who attend in connection with a local ME Support Group. IiME welcome all professionals who are working with, or have an interest in, ME/CFS.

    Background:
    The Invest in ME conferences have attracted presenters and delegates from fifteen countries and our DVDs of the conferences have been distributed to over 20 countries including Europe, USA, Canada, Australia and New Zealand.

    Myalgic Encephalomyelitis is a serious neurological illness (classified by the World Health Organisation under ICD-10-93.3) that causes severe problems for an estimated 250,000 people in the UK, of whom 25,000 are estimated to be children and young people.  It is five times more prevalent than HIV/AIDS in the UK and the leading cause of long term absence of children from school through sickness.

    The conference will be a unique opportunity to be informed of the latest research and information from some of the leading experts on ME/CFS in the areas of diagnosis, management, treatment, epidemiology and research.

    Conference Registration:

     

    Full details of the conference can be found at this address - click here.

    Should you have any further questions relating to the conference please contact us at meconference@investinme.org.

    We look forward to welcoming you to the conference,


     

    Invest in ME
    UK Registered Charity Nr. 1114035


     

    Invest in ME, PO BOX 561, Eastleigh SO50 0GQ, Hampshire, UK


     

    Support ME Awareness - Invest in ME

     

    www.investinme.org

    Mit der rechten Maustaste hier klicken, um Bilder downzuloaden. Um Ihre Privatsphäre besser zu schützen, hat Outlook den automatischen Download dieses Bilds vom Internet verhindert.

    6th Invest in ME International ME/CFS Conference 2011

    Conference News

     

     
     

     

    PRE-CONFERENCE  PRESENTATION EVENING

     

     

     

     

    Invest in ME are pleased to present -

     

     

     

     

    Thursday 19th May 2011, London, UK

    with

     


     

    Hillary Johnson Dr. Ian Gibson


     

     
     

     

    Welcome to a pre-conference evening presentation and refreshment buffet and listen to views from different sides of the Atlantic on how Science, and ME research in particular, has been affected and influenced by politics.

    From USA the author of Osler's Web returns to London to present for IiME. Hillary Johnson showed the extensive body of scientific evidence for the biological origins of Myalgic Encephalomyelitis (ME or ME/CFS) in her book  [see IiME Newsletter October 2008].

    Dr. Ian Gibson is uniquely qualified to comment on how science and politics have become intertwined. A scientist, politician and academic Dr. Gibson has an inside perspective on this  topic. 

    More details will be announced later.

    We expect great interest for this presentation and places are limited so we would advise an early booking. Price £25 per person. 

    The evening will consist of presentations and a refreshment buffet.

    Join Invest in ME, the conference presenters, researchers and other conference delegates for a chance to listen to two unique presentations and network with others.

    18:00, 19th May 2011 in Westminster, London

    In the first instance contact Invest in ME to reserve places by emailing us at this address -

    info@investinme.org

    More details will be made available on the Invest in ME web site shortly.
     

    For details of the 6th International ME/CFS Conference 2011 please visit the conference home page - click here   

     


     

    We invite you to join us 

     

     


     

     

    Invest in ME (Charity Nr 1114035)

     

     

    Support ME Awareness  -  Invest in ME

    www.investinme.org

     

     

     

    Mit der rechten Maustaste hier klicken, um Bilder downzuloaden. Um Ihre Privatsphäre besser zu schützen, hat Outlook den automatischen Download dieses Bilds vom Internet verhindert.